You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 259 No. 14, April 8, 1988 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Positron Emission Tomography in Oncology

Council on Scientific Affairs Report of the Positron Emission Tomography Panel; George M. Bohigian, MD; E. Harvey Estes, Jr, MD; Ira R. Friedlander, MD; William R. Kennedy, MD; John H. Moxley III, MD; Patricia J. Numann, MD; Paul S. Salva, PhD; William C. Scott, MD; Joseph H. Skom, MD; Richard M. Steinhilber, MD; Jack P. Strong, MD; Henry H. Wagner, Jr, MD; William R. Hendee, PhD; William T. McGivney, PhD; Joanna S. Fowler, PhD; Edward J. Hoffman, PhD; Steven M. Larson, MD; Heinrich R. Schelbert, MD; Markus Schwaiger, MD; Henry N. Wagner, Jr, MD; Alfred P. Wolf, PhD; Paul K. Strudler, PhD; William R. Hendee, PhD; Theodore C. Doege, MD, MS

JAMA. 1988;259(14):2126-2131.


Abstract

This report describes the current and potential uses of positron emission tomography in clinical medicine and research related to oncology. Assessment will be possible of metabolism and physiology of tumors and their effects on adjacent tissues. Specific probes are likely to be developed for target sites on tumors, including monoclonal antibodies and specific growth factors that recognize tumors. To date, most oncological applications of positron emission tomography tracers have been qualitative; in the future, quantitative metabolic measurements should aid in the evaluation of tumor biology and response to treatment.

(JAMA 1988;259:2126-2131)



Author Affiliations

St Louis, Chairman; Chicago, Resident Representative; Minneapolis; Los Angeles, Immediate Past Chairman; Syracuse, NY; Lubbock, Tex, Medical Student Representative; Tucson, Vice-Chairman; Chicago; Cleveland; New Orleans; Baltimore; Upton, NY; Los Angeles; Bethesda, Md; Los Angeles; Los Angeles; Baltimore, Council on Scientific Affairs Liaison; Upton, NY

From the Council on Scientific Affairs, American Medical Association, Chicago.


Footnotes

This report was submitted to the House of Delegates at the 1987 Annual Meeting as an informational report.

This report is not intended to be construed or to serve as a standard of medical care. Standards of medical care are determined on the basis of all of the facts and circumstances involved in an individual case and are subject to change as scientific knowledge and technology advance and patterns of practice evolve. This report reflects the views of scientific literature as of February 1987.

Reprint requests to Council on Scientific Affairs, American Medical Association, 535 N Dearborn St, Chicago, IL 60610 (William R. Hendee, PhD).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

National Cancer Institute Workshop Statement: Advances in Clinical Imaging Using Positron Emission Tomography, September 14-16, 1988
The Workshop Panel
Arch Intern Med 1990;150:735-739.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.